by: ASRM Office of Public Affairs
Published in ASRM Bulletin Volume 14, Number 19
With support from the Bill & Melinda Gates Foundation, FHI 360 has launched a project to support early testing of innovative approaches to developing a longer-acting injectable contraceptive (that lasts 6 to 12 months). This project is the first step toward bringing a game-changing injectable contraceptive to market, thereby expanding contraceptive access and choice for women around the world.
To further this effort, FHI 360 is offering a funding opportunity for proof-of-concept testing of candidates or approaches that have the potential to be developed into a longer-acting injectable. Proposals may include research that supports the development of new drugs, new formulations of existing drugs, or new methods of delivery and routes of administration for existing drugs. Proof-of-concept testing may include a wide variety of research activities such as formulation development, in-vitro testing, preclinical and/or clinical pharmacokinetic/pharmacodynamics studies.
Application guidelines and instructions are available at: http://www.fhi360.org/en/Research/res_longeractinginjectables.htm
The first stage of the application process is a 2-page Concept Paper which is due April 30, 2012. Questions can be emailed to LongerActingInjectable@fhi360.org
FHI 360 is a leading human development organization dedicated to improving lives by advancing integrated, locally driven solutions. http://aed.org/en/index.htm
The ASRM Bulletin is published by ASRM's Office of Public Affairs to inform Society members of important recent developments. Republication or any other use of the contents of the Bulletin without permission is prohibited. To request permission to quote or excerpt material from the Bulletin, contact Sean Tipton at email@example.com.